About Daan Biotherapeutics
Daan Biotherapeutics is a company based in Seoul (South Korea) founded in 2020 by J Y Han. Daan Biotherapeutics has raised $17.21 million across 1 funding round from investors including Shinhan Financial Group, Atinum Investment and KB Investment. Daan Biotherapeutics operates in a competitive market with competitors including Genprex, Bridge Biotherapeutics, Lineage Cell Therapeutics, Xcovery and Flame Biosciences, among others.
- Headquarter Seoul, South Korea
- Founders J Y Han
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17.21 M (USD)
in 1 rounds
-
Latest Funding Round
$17.21 M (USD), Series A
Jan 27, 2024
-
Investors
Shinhan Financial Group
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Daan Biotherapeutics
Daan Biotherapeutics has successfully raised a total of $17.21M through 1 strategic funding round. The most recent funding activity was a Series A round of $17.21 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Daan Biotherapeutics
Daan Biotherapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Shinhan Financial Group, Atinum Investment and KB Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare startups
|
Locked | Locked | Locked | |
|
Venture capital firm investing in tech startups
|
Locked | Locked | Locked | |
|
Strategic investments are made in high-growth companies by Paratus Investment.
|
Locked | Locked | Locked |
Investor details for Daan Biotherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Daan Biotherapeutics
Investment portfolio details for Daan Biotherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Daan Biotherapeutics
Detailed financials for Daan Biotherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Daan Biotherapeutics Comparisons
Peer comparison for Daan Biotherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Daan Biotherapeutics
Daan Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Genprex, Bridge Biotherapeutics, Lineage Cell Therapeutics, Xcovery and Flame Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for molecular-level cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Lineage Cell Therapeutics is focused on developing allogeneic cell therapies.
|
|
| Locked | Locked | Locked |
Kinase inhibitors are developed for non-small cell lung cancer treatment.
|
|
| Locked | Locked | Locked |
Inflammation-driven cancer and disease drugs are manufactured.
|
Detailed competitors of Daan Biotherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Daan Biotherapeutics
Complete news archive for Daan Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Daan Biotherapeutics
Daan Biotherapeutics was founded in 2020 and raised its 1st funding round 4 years after it was founded.
Daan Biotherapeutics is headquartered in Seoul, South Korea.
Byoung Chul Cho is the current CEO of Daan Biotherapeutics.
Daan Biotherapeutics is a funded company, having raised a total of $17.21M across 1 funding round to date.
Daan Biotherapeutics was founded in 2020 in Seoul, South Korea. Operations are centered in the biotechnology sector, where therapeutics for cancer treatment are developed. Immune-based cell therapies are focused on lung cancer, with T Cell Receptors (TCR) derived from natural killer cells used to target EGFR mutations. The company is led by founder J Y Han and CEO Byoung Chul Cho.
Daan Biotherapeutics's top competitors include Genprex, Lineage Cell Therapeutics and Xcovery.
Daan Biotherapeutics has 11 investors. Key investors include Shinhan Financial Group, Atinum Investment, KB Investment, Company K Partners, and Solasta Ventures.